The opioid epidemic killed approximately 806,000 Americans between 1999 and 2023.[s] This was not a natural disaster or an unforeseeable tragedy. This was opioid marketing fraud on an industrial scale: a corporate decision to sell a dangerous drug using deliberate lies, backed by regulators who failed to act when the evidence was overwhelming. The companies and families who profited knew what they were doing. The regulators who approved their claims had every opportunity to stop it. Both chose not to.
The thesis here is uncomfortable but necessary: what happened was not an accident, not a well-intentioned mistake that spiraled out of control. The opioid crisis was manufactured through opioid marketing fraud and calculated decisions that prioritized profit over the lives of millions of Americans.
The Lies That Built an Epidemic
When Purdue Pharma launched OxyContin in 1996, company executive Richard Sackler told attendees at the launch party to envision natural disasters: “an earthquake, a hurricane, or a blizzard.” The debut of OxyContin, he said, “will be followed by a blizzard of prescriptions that will bury the competition.”[s] This was not the language of a company hoping to help patients manage pain. This was the language of conquest.
The centerpiece of Purdue’s opioid marketing fraud was a single claim repeated endlessly to doctors: addiction rates were “less than 1%.” As early as 1997, Purdue’s promotional materials stated that “less than 1% of patients taking opioids actually become addicted,” that addiction was “rare,” and that concerns about psychological dependence were a “myth.”[s]
This claim was based on a one-paragraph letter to the editor published in the New England Journal of Medicine in 1980: the Porter and Jick letter. That letter described hospitalized patients receiving opioids under medical supervision for short periods, administered by hospital personnel.[s] It had nothing to do with outpatients taking OxyContin at home, unsupervised, for months or years. The study’s own author later said Purdue’s characterization “distorts the picture and it clearly underplays the risk.”[s]
The actual addiction rates in chronic pain patients? Studies documented rates between 3% and 34%: at minimum three times what Purdue claimed, and potentially more than thirty times higher.[s]
Opioid Marketing Fraud Was Deliberate
Purdue did not stumble into false advertising. The evidence shows opioid marketing fraud that was systematic and intentional. The company created false advertising documents claiming time-released OxyContin was less addictive than immediate-release alternatives. They sought out high-volume prescribers and pushed them to prescribe more.[s]
When addiction problems became undeniable, Purdue’s response was not to warn patients or restrict marketing. Richard Sackler’s 2001 strategy was to shift blame: “We have to hammer on the abusers in every way possible. They are the culprits and the problem. They are reckless criminals.”[s] The company blamed the victims of its own deception.
Purdue also cultivated relationships with elite medical institutions to lend credibility to its campaign. Massachusetts General Hospital received $3 million from Purdue since 2009 under an agreement that allowed the company to propose “areas where education in the field of pain is needed” and suggest curriculum.[s] Purdue’s New England staff was congratulated for “penetrating this account.” The company was not supporting medical education; it was buying influence to perpetuate its opioid marketing fraud.
The Regulators Who Watched
The FDA’s role in enabling this crisis deserves more scrutiny than it has received. When the agency approved OxyContin in 1995, it allowed something unprecedented: a claim on the label stating that “delayed absorption…is believed to reduce the abuse liabilityThe potential for a drug to be abused or cause addiction. Pharmaceutical companies must assess this risk during drug development. of the drug.” This was the first time the FDA had permitted such a claim for an opioid. The claim was scientifically baseless: Purdue had not conducted clinical studies to support it.[s]
The FDA also approved a broad indicationThe specific medical condition or disease that a drug is approved to treat by regulatory authorities like the FDA. for OxyContin instead of restricting it to severe pain from life-limiting illness. This gave Purdue license to market the drug for common conditions like low-back pain and fibromyalgia, where opioids were more likely to harm than help.[s]
By 2002, opioid prescribing had clearly risen beyond what could be clinically justified. The FDA convened an advisory committee to consider narrowing the indication. Eight of the ten outside experts had financial ties to pharmaceutical companies, including Purdue. They advised against restricting the marketing.[s] An opportunity to intervene early was squandered.
The revolving doorThe movement of personnel between government regulatory agencies and the industries they oversee, creating structural incentives for regulators to favor the companies they may later work for. between the FDA and the industry it regulates made matters worse. The two principal FDA reviewers who approved OxyContin both took positions at Purdue after leaving the agency.[s] Over two decades, several other FDA staff involved in opioid approvals followed the same path. When the regulators who approve drugs are looking toward future employment at the companies they regulate, the public cannot expect rigorous oversight.
The Reckoning That Wasn’t
In 2007, Purdue pleaded guilty to a felony charge of illegally misbrandingA legal violation in US food and drug law for labeling a product falsely or misleadingly about its contents, ingredients, or therapeutic claims. OxyContin. U.S. Attorney John Brownlee stated that the company, “with the intent to defraud and mislead, marketed and promoted OxyContin as less addictive, less subject to abuse and diversion, and less likely to cause tolerance and withdrawal than other pain medications.”[s] Purdue paid $634 million.[s]
This should have been the end. It was not. As Congress later documented, Purdue had generated more than $35 billion in revenue from OxyContin, and the Sackler family withdrew more than $10 billion from the company.[s] The 2007 fine represented a fraction of the profits. The executives who pleaded guilty received misdemeanor charges. The underlying opioid marketing fraud had been extraordinarily profitable, and the consequences were manageable.
The CDC identifies three waves in the opioid epidemic. The first began in the 1990s with increased prescribing of opioids: the direct result of the marketing campaign Purdue pioneered.[s] By the time the second and third waves arrived, driven by heroin and then fentanyl, the infrastructure of addiction had already been built. Millions of Americans had been made dependent on opioids through legitimate prescriptions obtained under false pretenses.
What This Should Teach Us
The opioid crisis was not an accident. It was opioid marketing fraud combined with regulatory captureThe process where a regulated industry shapes the legislation meant to regulate it, often resulting in rules that benefit the industry more than the public interest.: a pharmaceutical company that chose to lie about its product and a regulatory agency that was too compromised to stop it. The cost has been measured in human lives. The accountability has been minimal.
The uncomfortable truth is that this can happen again. The revolving door between the FDA and industry remains open. Advisory committees still include experts with financial ties to the companies whose products they evaluate. Pharmaceutical marketing still operates in the space between technical compliance and practical deception.
Understanding what happened with OxyContin is not merely historical. It is a warning. When corporate incentives align toward maximizing prescriptions, when regulators are captured by the industries they oversee, when lies can be profitable enough to absorb the fines: those are the conditions under which epidemics are manufactured. The opioid marketing fraud that killed hundreds of thousands was not a failure of information. It was a failure of accountability. Until that changes, the next epidemic is a matter of when, not if.
